FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387157033> ?p ?o ?g. }

• W4387157033 endingPage "118" @default.
• W4387157033 startingPage "1" @default.
• W4387157033 abstract "Pre-eclampsia is when high blood pressure develops after 20 weeks of pregnancy and either proteinuria, maternal end-organ dysfunction, or uteroplacental dysfunction causing fetal growth restriction also develops. The Fetal Medicine Foundation has created an algorithm (the FMF algorithm) that uses maternal factors in combination with biophysical and biochemical markers to identify people at high risk for pre-eclampsia so that they can been offered acetylsalicylic acid (Aspirin) as a preventive measure. We conducted a health technology assessment to evaluate the safety, effectiveness, and cost-effectiveness of a first-trimester population-wide screening program for pre-eclampsia risk that uses the FMF algorithm (the FMF-based screening program). We also evaluated the accuracy of the FMF algorithm, the budget impact of publicly funding the population-wide FMF-based screening program, and patient preferences and values.We performed a systematic literature search of the clinical evidence. We assessed the risk of bias of each study using the Risk of Bias in Non-randomized Studies-of Interventions tool and the Quality Assessment of Diagnostic Accuracy Studies-Comparative tool, and the quality of the body of evidence according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group criteria. We performed a systematic economic literature search and conducted a cost-effectiveness analysis comparing the FMF-based screening program to standard care (screening for risk of pre-eclampsia using maternal factors alone) from a public payer perspective. We also analyzed the budget impact of publicly funding a population-wide FMF-based screening program in Ontario. We spoke with people who have experience with pregnancy and preeclampsia and their family members through direct interviews to gather preferences and values surrounding pre-eclampsia and the potential screening program.We included nine studies in the clinical evidence review. The FMF-based screening program likely reduces the risk of pre-eclampsia with delivery at less than 37 weeks' gestation compared with standard care, when initiated at 11+0 to 13+6 weeks' gestation; risk ratios ranged from 0.64 (95% confidence interval [CI] 0.46-0.93) to 0.70 (95% CI 0.58-0.84) (GRADE: Moderate). It may reduce the risks of low birth weight (risk ratio 0.89 [95% CI 0.85-0.94]) and low Apgar score (risk ratio 0.73 [95% CI 0.63-0.85]) (GRADE: Low). Evidence on the effectiveness of the FMF-based screening program in reducing the risk of stillbirth and neonatal death was highly uncertain (GRADE: Very low). In addition, the FMF algorithm can improve the detection rate of pre-eclampsia with delivery at less than 37 weeks' gestation or at less than 34 weeks' gestation compared with conventional algorithms, although there are concerns about bias and applicability across studies. The population-wide FMF-based screening program is more effective and more costly than standard care. The incremental cost-effectiveness ratio of the population-wide FMF-based screening program compared with standard care is $3,446 per prevented case of pre-eclampsia with delivery at less than 37 weeks. The annual budget impact of publicly funding the population-wide FMF-based screening program in Ontario ranges from an additional $1.23 million in year 1 to $3.56 million in year 5, for a total of $8.50 million over the next 5 years. The population-wide FMF-based screening program was seen as valuable by those who have experienced pregnancy and their family members. Strong emphasis was placed on providing education and equitable access as part of any screening program, and participants valued the potential clinical benefits that the population-wide FMF-based screening program could provide.The FMF-based screening program is likely more effective than standard care in reducing the risk of pre-eclampsia with delivery at less than 37 weeks' gestation. Also, the FMF algorithm can improve the detection rate of pre-eclampsia with delivery at less than 37 weeks' gestation or at less than 34 weeks' gestation when compared with conventional algorithms. The population-wide FMF-based screening program is more effective and more costly than standard care. We estimate that publicly funding the population-wide FMF-based screening program in Ontario would result in additional costs of $8.50 million over the next 5 years. Pregnant people and their family members valued the potential equitable access, information, and clinical benefits that the population-wide FMF-based screening program could provide." @default.
• W4387157033 created "2023-09-30" @default.
• W4387157033 date "2023-01-01" @default.
• W4387157033 modified "2023-10-17" @default.
• W4387157033 title "First-Trimester Screening Program for the Risk of Pre-eclampsia Using a Multiple-Marker Algorithm: A Health Technology Assessment." @default.
• W4387157033 cites W1154833837 @default.
• W4387157033 cites W1597522315 @default.
• W4387157033 cites W1857778961 @default.
• W4387157033 cites W1917684112 @default.
• W4387157033 cites W1964206180 @default.
• W4387157033 cites W1975775758 @default.
• W4387157033 cites W1976042245 @default.
• W4387157033 cites W1979872571 @default.
• W4387157033 cites W1980067083 @default.
• W4387157033 cites W1980421688 @default.
• W4387157033 cites W1995101291 @default.
• W4387157033 cites W2019627649 @default.
• W4387157033 cites W2036015212 @default.
• W4387157033 cites W2047677041 @default.
• W4387157033 cites W2048460281 @default.
• W4387157033 cites W2049887195 @default.
• W4387157033 cites W2080230067 @default.
• W4387157033 cites W2095759878 @default.
• W4387157033 cites W2099514900 @default.
• W4387157033 cites W2130645342 @default.
• W4387157033 cites W2133039603 @default.
• W4387157033 cites W2146961353 @default.
• W4387157033 cites W2156098321 @default.
• W4387157033 cites W2164045626 @default.
• W4387157033 cites W2170500222 @default.
• W4387157033 cites W2260113709 @default.
• W4387157033 cites W2268289131 @default.
• W4387157033 cites W2299177375 @default.
• W4387157033 cites W2346358422 @default.
• W4387157033 cites W246286872 @default.
• W4387157033 cites W2531269403 @default.
• W4387157033 cites W2569868133 @default.
• W4387157033 cites W2592251773 @default.
• W4387157033 cites W2608579198 @default.
• W4387157033 cites W2609422999 @default.
• W4387157033 cites W2626253760 @default.
• W4387157033 cites W2730504020 @default.
• W4387157033 cites W2738649869 @default.
• W4387157033 cites W2767859123 @default.
• W4387157033 cites W2790823829 @default.
• W4387157033 cites W2790948098 @default.
• W4387157033 cites W2799515852 @default.
• W4387157033 cites W2808436993 @default.
• W4387157033 cites W2897870963 @default.
• W4387157033 cites W2900398263 @default.
• W4387157033 cites W2928591898 @default.
• W4387157033 cites W2941236069 @default.
• W4387157033 cites W2946525881 @default.
• W4387157033 cites W2956872982 @default.
• W4387157033 cites W2968918273 @default.
• W4387157033 cites W2971567043 @default.
• W4387157033 cites W2972496197 @default.
• W4387157033 cites W2974367350 @default.
• W4387157033 cites W2978654833 @default.
• W4387157033 cites W2987938051 @default.
• W4387157033 cites W3039401173 @default.
• W4387157033 cites W3042661563 @default.
• W4387157033 cites W3043503599 @default.
• W4387157033 cites W3045385144 @default.
• W4387157033 cites W3081062423 @default.
• W4387157033 cites W3081216910 @default.
• W4387157033 cites W3092985072 @default.
• W4387157033 cites W3141256924 @default.
• W4387157033 cites W3181738016 @default.
• W4387157033 cites W3201988987 @default.
• W4387157033 cites W3209729653 @default.
• W4387157033 cites W3216648933 @default.
• W4387157033 cites W4211203631 @default.
• W4387157033 cites W4226027230 @default.
• W4387157033 cites W4243714175 @default.
• W4387157033 cites W4280528926 @default.
• W4387157033 cites W4283738022 @default.
• W4387157033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37772268" @default.
• W4387157033 hasPublicationYear "2023" @default.
• W4387157033 type Work @default.
• W4387157033 citedByCount "0" @default.
• W4387157033 crossrefType "journal-article" @default.
• W4387157033 hasConcept C118552586 @default.
• W4387157033 hasConcept C12174686 @default.
• W4387157033 hasConcept C27415008 @default.
• W4387157033 hasConcept C2779234561 @default.
• W4387157033 hasConcept C2781276381 @default.
• W4387157033 hasConcept C2908647359 @default.
• W4387157033 hasConcept C38652104 @default.
• W4387157033 hasConcept C41008148 @default.
• W4387157033 hasConcept C54355233 @default.
• W4387157033 hasConcept C71924100 @default.
• W4387157033 hasConcept C86803240 @default.
• W4387157033 hasConcept C99454951 @default.
• W4387157033 hasConceptScore W4387157033C118552586 @default.
• W4387157033 hasConceptScore W4387157033C12174686 @default.
• W4387157033 hasConceptScore W4387157033C27415008 @default.
• W4387157033 hasConceptScore W4387157033C2779234561 @default.

• next